Clinical Trials Browser

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT06250972 2025-08-07

PTCA199-11

Phase 3 Recruiting

210 enrolled

Gastrointestinal

Pancreatic Adenocarcinoma

NCT02885753 2025-07-09

OSCAR

Phase 3 Recruiting

348 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT04861558 2025-05-30

EFFIPEC

Phase 3 Recruiting

213 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04415853 2025-05-18

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Phase 3 Recruiting

416 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT03750669 2025-05-13

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Phase 3 Completed

324 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02934529 2025-04-16

AIO-KRK-0114

Phase 3 Completed

673 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06899477 2025-03-28

Pre-Operative Treatment in REseCTable COlon CanceR

Phase 3 Not yet recruiting

714 enrolled

Gastrointestinal

Colonic Neoplasms

NCT01167725 2024-12-27

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Phase 3 Terminated

340 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT03430843 2024-10-26

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

512 enrolled 27 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT04927780 2024-08-28

PREOPANC-3

Phase 3 Recruiting

378 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06509126 2024-07-19

IMPROVE-2

Phase 3 Recruiting

500 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06501664 2024-07-15

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Phase 3 Not yet recruiting

360 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05954078 2024-05-20

Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

Phase 3 Recruiting

340 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06194734 2024-03-07

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Phase 3 Recruiting

490 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Phase 3 Completed

457 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms

NCT06123494 2024-01-16

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Phase 3 Recruiting

360 enrolled

Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Clinical Trials

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

MK-3475-C66

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

TRIBE-C

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

SOLARIS

FOBEAR

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

TroFuse-015

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

LAP100

Beacon-BTC

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

GRECCAR8

AIO-KRK-0418

RASolute 302

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

AtezoTRIBE2

NEXT-REGIRI

IROCAS

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

CheckMate 8HW

LIBImAb

LEFT-PANC

The Sagittarius Trial

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

PTCA199-11

OSCAR

EFFIPEC

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

AIO-KRK-0114

Pre-Operative Treatment in REseCTable COlon CanceR

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

PREOPANC-3

IMPROVE-2

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen